Home » Amgen's Xgeva delays prostate cancer metastasis
Amgen's Xgeva delays prostate cancer metastasis
May 18, 2011
Results from a phase III trial of Amgen's Xgeva have demonstrated that the drug is able to delay the progression of prostate cancer into the bone, which could increase its market potential, according to Pharma Times.
Data showed that Xgeva (denosumab), which is also marketed as Prolia for the treatment of osteoporosis, significantly improved the median bone metastasis-free survival by 4.2 months, a risk reduction of 15%, compared to placebo.
While no survival benefits were noted, the Xgeva study is reportedly the first randomized trial to show a significant reduction in the risk of bone metastasis for men with prostate cancer.
Upcoming Events
-
23Apr
-
07May
-
14May